Inhibitory proproteinowej konwertazy subtylizyny/keksyny 9 nowym, przełomowym narzędziem terapeutycznym w leczeniu dyslipidemii = Proprotein convertase subtilisin/kexin type 9 inhibitors are a new, groundbreaking therapeutic tool in the treatment of dyslipidemia

Łukasz Wołowiec, Joanna Banach, Daniel Rogowicz, Magdalena Grochowska, Walery Zukow, Władysław Sinkiewicz

Abstract


Wołowiec Łukasz, Banach Joanna, Rogowicz Daniel, Grochowska Magdalena, Zukow Walery, Sinkiewicz Władysław. Inhibitory proproteinowej konwertazy subtylizyny/keksyny 9 nowym, przełomowym narzędziem terapeutycznym w leczeniu dyslipidemii = Proprotein convertase subtilisin/kexin type 9 inhibitors are a new, groundbreaking therapeutic tool in the treatment of dyslipidemia. Journal of Education, Health and Sport. 2016;6(7):525-539. eISSN 2391-8306. DOI http://dx.doi.org/10.5281/zenodo.58882

http://ojs.ukw.edu.pl/index.php/johs/article/view/3716

 

 

 

The journal has had 7 points in Ministry of Science and Higher Education parametric evaluation. Part B item 755 (23.12.2015).

755 Journal of Education, Health and Sport eISSN 2391-8306 7

© The Author (s) 2016;

This article is published with open access at Licensee Open Journal Systems of Kazimierz Wielki University in Bydgoszcz, Poland

Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium,

provided the original author(s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License

(http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited.

This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted, non commercial

use, distribution and reproduction in any medium, provided the work is properly cited.

The authors declare that there is no conflict of interests regarding the publication of this paper.

Received: 02.07.2016. Revised 25.07.2016. Accepted: 28.07.2016.

 

 

Inhibitory proproteinowej konwertazy subtylizyny/keksyny 9 nowym, przełomowym narzędziem terapeutycznym w leczeniu dyslipidemii

Proprotein convertase subtilisin/kexin type 9 inhibitors are a new, groundbreaking therapeutic tool in the treatment of dyslipidemia

 

Łukasz Wołowiec1, Joanna Banach1, Daniel Rogowicz1, Magdalena Grochowska1, Walery Zukow2, Władysław Sinkiewicz1

 

1 II Katedra Kardiologii, Wydział Nauk o Zdrowiu, Uniwersytet Mikołaja Kopernika w Toruniu

2 Instytut Kultury Fizycznej, Wydział Kultury Fizycznej, Zdrowia i Turystyki, Uniwersytet Kazimierza Wielkiego w Bydgoszczy

 

 

 

Streszczenie

Aktualnie najczęściej stosowaną grupą leków hipolipemizujących są statyny, które skutecznie redukują ryzyko niekorzystnych zdarzeń sercowo-naczyniowych w profilaktyce zarówno pierwotnej, jak i wtórnej. Stosowanie statyn może się jednak wiązać z nietolerancją tej grupy leków i występowaniem działań niepożądanych, których częstość zwiększa się w przypadku terapii skojarzonej z innymi lekami hipolipemizującymi. Ponadto u kilku procent chorych pomimo zastosowania skojarzonej terapii lekami hipolipemizującymi, nie udaje się osiągnąć docelowych wartości stężenia cholesterolu LDL (z ang. low-density lipoprotein – LDL, LDL-C). Nowa grupa leków - inhibitory proproteinowej konwertazy subtylizyny/keksyny 9 (PCSK9), które regulują stężenie receptora dla LDL-C, wydają się być nowym, skutecznym narzędziem terapeutycznym, stosowanym celem osiągnięcia docelowych wartości cholesterolu LDL. Celem pracy było przedstawienie metabolizmu cholesterolu w organizmie człowieka, znaczenia skutecznej terapii zaburzeń gospodarki lipidowej, aktualnego stanu wiedzy na temat białka PCSK9 i jego inhibitorów. Opisano wyniki najważniejszych badań klinicznych z inhibitorami PCSK-9.

 

Słowa kluczowe: cholesterol, proproteinowa konwertaza białkowa subtylizyna/keksyna typu 9 (PCSK9), inhibitory PCSK9.

 

 

Abstract

Statins are currently the most frequenly used  group of lipid-lowering drugs. This group of drugs can effectively reduce the risk of adverse cardiovascular diseases in both primary and secondary prevention, however,  their impementation may lead to intolerance and other side effects, the frequency of which increases in the case of a combined therapy with other lipid-lowering drugs. Additionally, in spite of the therapy a litte percenatge of the patients still cannot reach the target concentartion of LDL cholesterol. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (a  new class of drugs  that regulate the concentration of LDL cholesterol receptor) seem to be a  new and effective therapeutic tool used to reach the target level of LDL cholesterol. The aim of the study was to present the cholesterol metabolism in human body, the significance of an effective therapy for lipid disorders as well as the current knowledge of the PCSK9 protein and its inhibitors.

 

Key words: cholesterol, proprotein convertase subtilisin/kexin type (PCSK9), PCSK9 inhibitors.


Keywords


cholesterol, proproteinowa konwertaza białkowa subtylizyna/keksyna typu 9 (PCSK9), inhibitory PCSK9, cholesterol, proprotein convertase subtilisin/kexin type (PCSK9), PCSK9 inhibitors.

Full Text:

PDF (Polski)

References


Ahmad Z. Statin intolerance. Am J Cardiol 2014;15:1765–71.

Zdrojewski T, Rutkowski M, Bandosz P i wsp. Prevalence and control of cardiovascular risk factors in Poland. Assumptions and objectives of the NATPOL 2011 Survey. Kardiol Pol 2013;71:381–92.

Lubert Stryer. Biochemia. Warszawa: Wydawnictwo naukowe PWN; 2003.

Bańkowski E. Biochemia. Podręcznik dla studentów uczelni medycznych. Wrocław: Elsevier Urban & Partner; 2009.

Cichosz G, Czeczot H. Kontrowersje wokół cholesterolu pokarmowego. Pol Merkur Lek 2012;33:39–42.

Nowicka G. Zaburzenia lipidowe. Poznań: Termedia Wydawnictwa Medyczne; 2010.

Michajlik A, Bartnikowska E. Lipidy i lipoproteiny osocza. Warszawa: Wyd. Lek. PZWL; 1999.

Brown M, Goldstein J. A receptor-mediated pathway for cholesterol homeostasis. Angew Chem In Ed Engl 1986;25:34–47. Angew Chem In Ed Engl.

Lagor W, Millar J. Overview of the LDL receptor: relevance to cholesterol metabolism and future approaches for the treatment of coronary heart disease. J Recept Ligand Channel Res 2010;3:1–14.

Zhang H, Temel RE, Martel C. Cholesterol and lipoprotein metabolism: Early Career Committee contribution. Arterioscler Thromb Vasc Biol 2014;34:1791–4.

Li J, Tumanut C, Gavigan JA i wsp. Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity. Biochem J 2007;406:203–7.

McNutt MC, Lagace TA, Horton JD. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J Biol Chem 2007;282:20799–803.

Zhang DW, Lagace TA, Garuti R i wsp. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 2007;282:18602–12.

Maxwell KN, Soccio RE, Duncan EM i wsp. Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J Lipid Res 2003;44:2109–19.

Careskey HE, Davis RA, Alborn WE i wsp. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res 2008;49:394–8.

Rashid S, Curtis DE, Garuti R i wsp. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A. 2005;102:5374–9.

Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence Variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006:1264–72.

Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009;50:172–7.

Robinson JG, Farnier M, Krempf M i wsp. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. N Engl J Med 2015;372: 1489-99.

Moriarty PM, Thompson PD, Cannon CP i wsp. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol 2015;9:758–69.

Kereiakes DJ, Robinson JG, Cannon CP i wsp. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. Am Heart J 2015;169:906–915.

Cannon CP, Cariou B, Blom D i wsp. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J 2015;36:1186–94.

Bays H, Gaudet D, Weiss R i wsp. Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial. J Clin Endocrinol Metab 2015;100:3140–8.

Robinson JG, Colhoun HM, Bays HE i wsp. Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies. Clin Cardiol 2014;37:597–604.

Farnier M, Jones P, Severance R i wsp. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial. Atherosclerosis 2016;244:138–46.

Kastelein JJ, Ginsberg HN, Langslet G i wsp. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J 2015;36:2996–3003.

Koren MJ, Lundqvist P, Bolognese M i wsp. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol 2014;63:2531–40.

Sabatine MS, Giugliano RP, Wiviott SD i wsp. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. N Engl J Med 2015;372: 1500-9.

Stroes E, Colquhoun D, Sullivan D i wsp. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 2014;63:2541–8.

Frederick JR, Evan A Stein, Robert Dufour, MD, Traci Turner, MD, Fernano Civeira, MD, Prof Lesley Burgess, MB, Gisle Langslet, MD, Prof Russell Scott, MD, Prof Anders G Olsson, MD, David Sullivan, MD, G Kees Hovingh, MD, Bertrand Cariou, MD, Ioanna Gouni-Berthold, MD, Ransi Somaratne, Ian Bridges, Rob Scott, Scott M Wasserman DG. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2015;385:331–40.

Raal F, Honarpour N, Blom DJ i wsp. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 2015;385:341–50.

http://www.prnewswire.com/news-releases/amgen-completes-enrollment-in-large-cardiovascular-outcomes-trial-of-repatha-evolocumab-in-patients-with-high-cholesterol-and-clinically-evident-cardiovascular-disease-300094614.html

Ballantyne CM, Neutel J, Cropp A i wsp. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol 2015;115:1212–21.

http://press.pfizer.com/press-release/bococizumab-rn316-significantly-reduced-ldl-cholesterol-statin-treated-adults-high-cho




DOI: http://dx.doi.org/10.5281/zenodo.58882

Refbacks

  • There are currently no refbacks.




Copyright (c) 2016 Łukasz Wołowiec, Joanna Banach, Daniel Rogowicz, Magdalena Grochowska, Walery Żukow, Władysław Sinkiewicz

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Journal of Education, Health and Sport formerly Journal of Health Sciences

Declaration on the original version.

Editors indicates that the main version of the magazine is to issue a "electronic".

The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019.

1223 Journal of Education, Health and Sport eISSN 2391-8306 7

ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

Archives 2011 - 2014

PBN 2011 - 2014

https://pbn.nauka.gov.pl/sedno-webapp/search?search&searchCategory=WORK&filter.inJournal=36616

POL-index 2011 - 2014

https://pbn.nauka.gov.pl/polindex-webapp/browse/journal/journal-32a319c5-a850-4f44-ba70-1418a6087655

BASE 2011 - 2014

https://www.base-search.net/Search/Results?lookfor=Journal+of+Health+Sciences+%28Radom%29&type=all&oaboost=1&ling=1&name=&thes=&refid=dcrespl&newsearch=1

http://elibrary.ru/contents.asp?titleid=37467

http://journal.rsw.edu.pl/index.php/JHS/issue/archive

Indexed in Bases, Bazy indeksacyjne: ERIH Plus, Worldcat, PBN/POL-Index, ICI Journals Master List, Directory of Open Access Journals (DOAJ), ZBD, Ulrich's periodicals, Google Scholar, Polska Bibliografia Lekarska

US NLM = 101679844

101679844 - NLM Catalog Result - NCBI

https://www.ncbi.nlm.nih.gov/nlmcatalog/101679844

Find a library that holds this journal: http://worldcat.org/issn/23918306

Journal Language(s): English 

PBN Poland

https://pbn.nauka.gov.pl/sedno-webapp/journals/49068

POL-index

https://pbn.nauka.gov.pl/polindex-webapp/browse/journal/journal-c39c8169-88d2-45db-9e7f-d948ce9981c4

BASE

https://www.base-search.net/Search/Results?join=AND&bool0[]=AND&lookfor0[]=2391-8306&type0[]=all&page=11&l=pl&oaboost=1&refid=dcpagepl

Redaction, Publisher and Editorial Office

Instytut Kultury Fizycznej Uniwersytet Kazimierza Wielkiego w Bydgoszczy, Institute of Physical Education Kazimierz Wielki University in Bydgoszcz, Poland 85-091 Bydgoszcz ul. Sportowa 2  www.ukw.edu.pl Copyright by Instytut Kultury Fizycznej UKW w Bydgoszczy http://ojs.ukw.edu.pl/index.php/johs  Open Access ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

The journal has been approved for inclusion in ERIH PLUS.

The ERIH PLUS listing of the journal is available at https://dbh.nsd.uib.no/publiseringskanaler/erihplus/periodical/info?id=485984

SIC Science citation index (calculated on the basis of TCI and Page Rank) 0

Russian Impact factor 0.16

Indexed in Index Copernicus Journals Master List.

http://journals.indexcopernicus.com/Journal+of+Education+Health+and+Sport,p24782242,3.html

ICV 2018 = 95.95 ICV 2017 = 91.30 ICV 2016 = 84.69 ICV 2015 = 93.34 ICV 2014 = 89.51 Standardized Value: 8.27 ICV 2013: 7.32 ICV 2012: 6.41 ICV 20115.48

The InfoBase Index IBI Factor for the year 2015 is 3.56 in InfoBase Index.com.

Website: www.infobaseindex.com

Universal Impact Factor 1.78 for year 2012. (http://www.uifactor.org/AppliedJournals.aspx)

Indexed in Polish Scholarly Bibliography (PBN) (PBN Polska Bibliografia Naukowa) (https://pbn.nauka.gov.pl/journals/36616)

is a portal of the Polish Ministry of Science and Higher Education, collecting information on publications of Polish scientists and on Polish and foreign scholarly journals. Polish Scholarly Bibliograhpy is a part of POL-on - System of Information on Higher Education. It is operated by the Interdisciplinary Centre for Mathematical and Computational Modelling, University of Warsaw.

Indexed in Russian Sciences Index Российский индекс научного цитирования (РИНЦ) http://elibrary.ru/contents.asp?titleid=37467

Indexed in Arianta Polish scientific and professional electronic journals Aneta Drabek i Arkadiusz Pulikowski

(http://www1.bg.us.edu.pl/bazy/czasopisma/czasop_full.asp?id=3595)